A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

This study is testing a cutting-edge treatment called CAR-T cell therapy — where a patient's own immune cells are reprogrammed to attack the disease — in people with progressive forms of multiple sclerosis (MS). It is designed for patients whose MS keeps getting worse despite standard treatments. **You may be eligible if...** - You are between 18 and 65 years old - You have a confirmed diagnosis of MS (McDonald 2017 criteria) - You have progressive MS that is actively getting worse - You have antibodies against chickenpox (VZV) or have received the Shingrix vaccine at least 4 weeks before treatment - You have antibodies against Epstein-Barr virus (EBV) - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have relapsing-remitting MS (this is for progressive forms only) - You do not meet the immune or organ function requirements - You are outside the age range - You have not been vaccinated against shingles and do not have existing VZV immunity Talk to your doctor to see if this trial is right for you.